The Latest Cardiac and Vascular News
– This new indication is based on the EMPEROR-Reduced trial, which showed a significant 25 percent reduction in the combined relative risk versus placebo of cardiovascular death or hospitalization for heart failure with reduced ejection fraction in adults with or without diabetes and an eGFR of ≥20ml/min/1.73 m2 – Heart failure […]
VANCOUVER and MINNEAPOLIS, June 18, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced the publication of an article entitled, “Safety and Efficacy of Coronary Sinus Narrowing in Chronic Refractory Angina: Insights from the RESOURCE Study” in the International Journal of Cardiology. The article, authored by Francesco […]
PORTLAND, Ore., June 17, 2021 /PRNewswire/ — VisCardia Inc., a privately held medical device developer, announced today it has been selected to participate in MedTech Innovator’s Annual Showcase and Accelerator Program. The selection process reduced 1,100 applicants from over 50 countries to 195 candidate companies that presented their technology to teams of senior […]
SAN DIEGO and PARIS, June 17, 2021 (GLOBE NEWSWIRE) — Rancho Santa Fe Bio, Inc. (“RSF Bio” or the “Company”), a San Diego, California-based clinical-stage cardiovascular platform company, today announced that it has entered into an exclusive worldwide license agreement with Sanofi, a global biopharmaceutical company. This agreement provides RSF […]
NIVA|HF is an investigational device designed to monitor the venous waveform, a novel physiologic signal, in heart failure patients. As a Breakthrough Device, NIVA|HF will receive pre-market developmental assistance and prioritized regulatory review from FDA. NIVA|HF is the first application of VoluMetrix’s proprietary venous waveform technology. NASHVILLE, Tenn., June 15, 2021 /PRNewswire/ […]
JenaValve Marks the 100th Implant of the Trilogy™ Heart Valve System IRVINE, Calif., June 15, 2021 (GLOBE NEWSWIRE) — JenaValve Technology, Inc., developer, and manufacturer of a novel transcatheter aortic valve replacement (TAVR) system, is pleased to announce today the 100th global implant of the Trilogy™ Heart Valve System. This milestone […]
Top Line Results of METEORIC-HF Expected in Early 2022 Company Plans to Submit NDA in 2H 2021 Based on Positive Results of GALACTIC-HF SOUTH SAN FRANCISCO, Calif., June 15, 2021 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the completion of patient enrollment in METEORIC-HF (Multicenter Exercise Tolerance Evaluation of Omecamtiv Mecarbil Related to Increased Contractility […]
Provides Incremental Reimbursement in Hospital Outpatient Setting SANTA CLARA, Calif., June 11, 2021 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, announced today that the Centers for Medicare & Medicaid Services (CMS) granted approval for a Transitional Pass-Through (TPT) payment for […]
OXFORD, England, June 14, 2021 /PRNewswire/ — GENinCode UK Limited, the cardiovascular disease company focused on predictive genetics for the prevention of cardiovascular disease, announces its partnership with EVERSANA Life Sciences LLC (“EVERSANA”) as its launch and commercialisation partner to access the United States market for the GENinCode portfolio of polygenic cardiovascular disease (“CVD”) products focused […]
– Exploratory biomarker analyses suggest possible cardiac disease improvements and renal response – BORDENTOWN, N.J. & BOSTON–(BUSINESS WIRE)–Caelum Biosciences and Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced new Phase 2 safety and tolerability data for CAEL-101, a potentially first-in-class amyloid fibril targeted therapy, in combination with standard-of-care (SoC) therapy in patients with AL […]
